Alivus Life Sciences Limited has informed the Exchange about General Updates
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences has received an Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Dahej, Gujarat, with a 'No Action Indicated' (NAI) classification. This follows a USFDA inspection conducted at the facility between May 26 and May 30, 2025. The NAI status means the USFDA found no objectionable conditions and requires no further action. The Dahej facility is part of the company's Special Economic Zone (SEZ) operations and is important for its active pharmaceutical ingredient (API) business.
This is a positive development for Alivus shareholders, as a clean USFDA inspection removes regulatory uncertainty and allows uninterrupted exports of APIs to the US market. A clean EIR with NAI classification typically reinforces the company's compliance standing and supports business continuity with US customers.